热门资讯> 正文

Genmab reports Q2 Darzalex net sales of $3.54 billion

2025-07-16 18:48

Genmab A/S (GMAB) said Wednesday that net sales of Darzalex in the second quarter of 2025 totaled $3,539 million.
Net trade sales were $2,017 million in the U.S. and $1,521 million in the rest of the world.
Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and SC products, under the exclusive worldwide license to J&J (JNJ) to develop, manufacture, and commercialize daratumumab.

More on Genmab

Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One
Genmab A/S: Transitioning From Royalty Model To Commercial-Stage Oncology
Genmab A/S (GMAB) Q1 2025 Earnings Conference Call Transcript
J&J, Genmab win FDA AdCom backing for multiple myeloma therapy
Seeking Alpha’s Quant Rating on Genmab

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。